Kura Oncology (NASDAQ:KURA) Stock Price Up 7.5%

Kura Oncology, Inc. (NASDAQ:KURAGet Free Report) was up 7.5% during trading on Wednesday . The company traded as high as $22.82 and last traded at $22.61. Approximately 541,949 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 1,580,038 shares. The stock had previously closed at $21.04.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on KURA shares. Wedbush restated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research report on Wednesday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Wednesday. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, February 12th. Mizuho began coverage on Kura Oncology in a research note on Friday, December 22nd. They set a “buy” rating and a $26.00 price target on the stock. Finally, JMP Securities lifted their price target on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research note on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.28.

View Our Latest Research Report on KURA

Kura Oncology Stock Down 1.9 %

The company has a fifty day moving average price of $18.47 and a 200 day moving average price of $12.80. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURAGet Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same period in the previous year, the firm posted ($0.49) EPS. On average, equities analysts anticipate that Kura Oncology, Inc. will post -2.35 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Troy Edward Wilson sold 91,052 shares of the business’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $20.23, for a total transaction of $1,841,981.96. Following the sale, the chief executive officer now directly owns 559 shares in the company, valued at approximately $11,308.57. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Kathleen Ford sold 1,496 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares in the company, valued at approximately $384,515.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Troy Edward Wilson sold 91,052 shares of the stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the sale, the chief executive officer now owns 559 shares of the company’s stock, valued at $11,308.57. The disclosure for this sale can be found here. Insiders have sold 96,919 shares of company stock valued at $1,946,415 in the last 90 days. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE increased its holdings in Kura Oncology by 45.0% in the 4th quarter. US Bancorp DE now owns 2,097 shares of the company’s stock worth $30,000 after buying an additional 651 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Kura Oncology by 46.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,710 shares of the company’s stock worth $50,000 after buying an additional 1,501 shares during the period. Signaturefd LLC lifted its holdings in shares of Kura Oncology by 40.4% in the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after buying an additional 1,449 shares during the period. Royal Bank of Canada lifted its stake in shares of Kura Oncology by 81.5% during the 2nd quarter. Royal Bank of Canada now owns 6,801 shares of the company’s stock worth $72,000 after purchasing an additional 3,053 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Kura Oncology by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after purchasing an additional 6,692 shares during the last quarter.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.

See Also

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.